Anal adenocarcinoma is a rare cancer that forms in the glandular lining cells of the anal canal, accounting for roughly one in eight anal cancer diagnoses. It behaves very differently from squamous cell carcinoma, the far more common type of anal cancer, and generally carries a worse prognosis. Because it is uncommon and its symptoms overlap with everyday conditions like hemorrhoids, it is frequently diagnosed late and treated using strategies borrowed from colorectal cancer rather than from a robust evidence base of its own.
How Common Is Anal Adenocarcinoma
Most anal cancers are squamous cell carcinomas, which arise from the flat cells lining the lower anal canal. In a large U.S. analysis spanning over three decades, squamous cell carcinoma made up about 82% of anal cancer cases, while adenocarcinoma accounted for roughly 12%.1Cancer Epidemiology, Biomarkers & Prevention. Anal Cancer Incidence in the United States, 1977–2011: Distinct Patterns by Histology and Behavior Melanoma and other rare types filled the remaining fraction. Unlike squamous cell anal cancer, whose incidence has been climbing for years, the rate of anal adenocarcinoma has stayed relatively flat.2PubMed Central. Changing Patterns of Anal Canal Carcinoma in the United States
The demographics differ between the two types as well. Squamous cell anal cancer is more common in women and in non-Hispanic white populations, while anal adenocarcinoma occurs more often in men and at higher rates among Black populations.1Cancer Epidemiology, Biomarkers & Prevention. Anal Cancer Incidence in the United States, 1977–2011: Distinct Patterns by Histology and Behavior These differences are not just statistical curiosities; they hint at distinct underlying causes and may affect how aggressively clinicians should screen certain groups.
What Causes Anal Adenocarcinoma
The relationship between HPV and anal cancer is well established for squamous cell carcinoma, where high-risk HPV types 16 and 18 are considered a necessary cause.3PubMed Central. Prevalence of HPV in anal cancer: exploring the role of infection and inflammation For adenocarcinoma, the picture is more complicated. Research on 74 primary anal canal adenocarcinomas identified two distinct subtypes based on their cellular origin. One type arises from the anal glands and transitional zone lining the upper anal canal. The other resembles colorectal cancer in its molecular markers. Among the anal gland type, about 42% of tested cases were HPV-positive, while none of the colorectal-type tumors showed HPV infection.4Journal of Clinical and Translational Pathology. A Review and Update on Epithelial Tumors of the Anal Canal So HPV plays a role in some anal adenocarcinomas but clearly not all of them.
Chronic inflammatory conditions in the perianal region are another recognized driver. People with Crohn’s disease who have anal or perianal involvement, such as fistulas or abscesses, face a substantially elevated risk. In one cohort study of patients with anal or perianal Crohn’s lesions, the presence of those lesions was the strongest factor associated with developing anal cancer, with an odds ratio above 11 compared to Crohn’s patients without perianal disease.5PubMed. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease Perianal fistula-related adenocarcinoma specifically emerged in that group, underscoring that longstanding fistula tracts can become a breeding ground for malignant transformation.
Rare predisposing conditions also appear in the literature. Chronic suppurative hidradenitis (a painful skin condition causing abscesses and scarring in areas like the groin and buttocks) has been linked to perineal mucinous adenocarcinoma in isolated cases, though this association is extremely rare.6International Journal of Surgery Case Reports. Mucinous adenocarcinoma associated with chronic suppurative hidradenitis: Report of a case and review of the literature The running theme is that years of chronic inflammation and tissue damage in the anal region appear to increase susceptibility, regardless of the specific disease causing that inflammation.
Two Subtypes With Different Biology
The distinction between the anal gland type and the colorectal type is not just academic. In the largest case series, about 35% of anal adenocarcinomas showed the molecular fingerprint of anal gland or transitional zone origin, staining positive for the protein marker CK7 and negative for CK20 and CDX2. The remaining 65% displayed the opposite pattern, resembling colorectal tumors.7British Journal of Cancer. A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine The anal gland type, which can also be confirmed by CK7 and CK19 positivity on biopsy, arises from the small glands within the anal canal wall itself.8PubMed Central. Adenocarcinoma arising from an anal gland-Report of a case
These two subtypes differ in their causes, immune environment, and patterns of gene mutations, which has led researchers to propose that HPV status could serve as a practical classification tool for planning treatment.4Journal of Clinical and Translational Pathology. A Review and Update on Epithelial Tumors of the Anal Canal The colorectal type shares more genetic overlap with rectal cancer, while the anal gland type has its own distinct molecular landscape. Understanding which subtype a patient has could eventually guide whether to treat it more like a rectal cancer or as its own separate entity.
Symptoms and Why They Get Missed
The most common symptoms of anal adenocarcinoma are anal pain, rectal bleeding, and a mass near or around the anus. In a survey of anal gland adenocarcinoma cases, pain was reported by about 58% of patients, bleeding by 40%, and a palpable perianal mass by 37%.9PubMed. Adenocarcinoma of the anal glands. Results of a survey Other symptoms can include changes in bowel habits, a sense of fullness or pressure in the anal area, and sometimes perianal itching or moisture.
The problem is that every one of those symptoms is far more commonly caused by something benign. Hemorrhoids, anal fissures, and perianal eczema are vastly more prevalent, and both patients and clinicians tend to assume a benign explanation first. Case reports document repeated misdiagnosis: one patient with anal adenocarcinoma and associated perianal Paget’s disease (a skin condition) spent two years being treated for hemorrhoids and eczema before the cancer was identified.10PubMed Central. Anal adenocarcinoma with perianal Paget’s disease: A case report Similarly, cases of anal squamous cell carcinoma have been documented as being initially treated as chronic anal fissures, particularly when the cancer was small or located in an atypical position.11PubMed Central. A Case Series of Anal Carcinoma Misdiagnosed as Idiopathic Chronic Anal Fissure The takeaway for anyone reading this: if you have anal symptoms that do not improve with standard treatment, or if a fissure is in an unusual location or has hardened edges, push for a biopsy rather than accepting a benign diagnosis indefinitely.
How It Is Diagnosed and Staged
Diagnosis starts with a physical exam and biopsy of any suspicious tissue. Once adenocarcinoma is confirmed, imaging determines how far the cancer extends locally and whether it has spread. Joint European and American guidelines recommend pelvic MRI and endoanal ultrasound as standard tools. MRI gives a detailed picture of the tumor’s relationship to surrounding structures and can identify enlarged lymph nodes, while endoanal ultrasound works best for smaller tumors. CT scans of the chest, abdomen, and pelvis with contrast are used to check for distant spread.12PubMed Central. An Updated Review on Imaging and Staging of Anal Cancer—Not Just Rectal Cancer
PET/CT adds another layer. A systematic review and meta-analysis found that PET/CT detected primary tumors with 99% sensitivity, compared to 67% for CT alone, and identified involved inguinal lymph nodes with about 93% sensitivity.13PubMed Central. PET imaging in anal canal cancer: a systematic review and meta-analysis PET/CT changed the disease stage in a meaningful proportion of patients, upstaging anywhere from 5% to nearly 38% and downstaging 8% to 27%. Those shifts led to modified treatment plans in up to about 59% of cases, mainly through adjustments to radiation dose or field.13PubMed Central. PET imaging in anal canal cancer: a systematic review and meta-analysis In practical terms, PET/CT can catch disease that CT misses and keep a patient from receiving the wrong treatment plan.
Treatment Approach
Here is where anal adenocarcinoma diverges sharply from squamous cell anal cancer. For squamous cell tumors, chemoradiation (typically with 5-fluorouracil and mitomycin C) is the established first-line treatment and often cures the disease without surgery.14PubMed Central. Evolution of the Role of Radiotherapy for Anal Cancer Anal adenocarcinoma does not respond as reliably to radiation-based protocols, so surgery plays a much larger role.
The operation most commonly performed is an abdominoperineal resection, or APR, which removes the anus, rectum, and part of the sigmoid colon, and results in a permanent colostomy. A study of patients with nonmetastatic anal adenocarcinoma found that those who had an APR had a five-year survival rate of about 58%, compared to 30% for patients treated with radiation alone. The hazard of death for radiation-only patients was roughly 2.8 times higher than for those who underwent surgery.15PubMed. Abdominal perineal resection improves survival for nonmetastatic adenocarcinoma of the anal canal
Current consensus favors combining surgery with chemoradiation rather than relying on either alone. A case report and literature review summarized the general agreement that a multimodal approach, combining radical surgical resection with preoperative or postoperative chemoradiation, achieves the best outcomes.16Zenodo. Anal canal adenocarcinoma locally treated with abdominoperineal resection after chemoradiotherapy: case report and review of literature The timing of surgery relative to chemoradiation appears to matter. Patients who underwent APR within six months of completing chemoradiation had a median survival of about 88 months, compared to roughly 58 months for those whose surgery came later.17PubMed. Survival Outcomes and Patterns of Management for Anal Adenocarcinoma
Prognosis Compared to Other Cancers
Anal adenocarcinoma carries a grimmer prognosis than both squamous cell anal cancer and rectal adenocarcinoma, even though the latter might seem like a closely related disease. One large study found a median overall survival of about 33 months for anal adenocarcinoma, compared to 118 months for squamous cell anal cancer and 68 months for rectal adenocarcinoma. After adjusting for age, stage, grade, and other factors, anal adenocarcinoma still had significantly worse outcomes than either comparison group.18PubMed. Comparative Survival of Patients With Anal Adenocarcinoma, Squamous Cell Carcinoma of the Anus, and Rectal Adenocarcinoma
A separate retrospective study echoed these findings, reporting five-year survival of about 48% for anal adenocarcinoma versus about 82% for rectal adenocarcinoma. Even when restricted to patients who received the same combination of chemoradiation and surgery, the anal adenocarcinoma group still fared worse, with five-year survival around 42% compared to 86% for the rectal group. After adjusting for cancer stage and treatment, having a tumor in the anal canal was independently associated with about 2.7 times the risk of death compared to the rectum.19Indian Journal of Gastroenterology. Survival outcomes of anal adenocarcinoma versus rectal adenocarcinoma: A retrospective cohort study
The factors consistently linked to worse outcomes include older age, higher tumor and nodal stage, male sex, having other health conditions, and being treated at a non-academic center.17PubMed. Survival Outcomes and Patterns of Management for Anal Adenocarcinoma This last point is worth noting: because the disease is rare, centers that see a higher volume of cases may have more experience tailoring the multimodal approach.
Advanced and Metastatic Disease
For patients whose cancer has spread beyond the pelvis, treatment shifts to palliative systemic therapy. Much of the available data on metastatic anal cancer focuses on squamous cell carcinoma, but the chemotherapy regimens used for adenocarcinoma tend to mirror those used for advanced colorectal cancer, given the molecular overlap of the colorectal subtype. A study of patients with advanced anal cancer treated with first-line platinum-fluoropyrimidine combinations reported an objective response rate of about 34%, with a median progression-free survival of roughly six months. Paclitaxel-based regimens showed a somewhat higher response rate at about 53%, though the sample was small. Five-year overall survival in the metastatic setting was approximately 15%.20The Oncologist. Platinum‐Fluoropyrimidine and Paclitaxel‐Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients
An international randomized trial comparing cisplatin plus fluorouracil against carboplatin plus paclitaxel in advanced anal cancer found no difference in response rate, but the carboplatin-paclitaxel combination had lower toxicity and a trend toward longer survival, leading to its emergence as a preferred option.21PubMed Central. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct Triple combinations adding a taxane to cisplatin and fluorouracil have also shown promising response rates with tolerable side effects.22PubMed. New approaches in palliative systemic therapy of anal squamous cell carcinoma
Molecular Profiling and Emerging Therapies
Genomic profiling is beginning to reveal how anal adenocarcinoma differs molecularly from its colorectal lookalike. A Japanese study of advanced anal adenocarcinoma found that the most commonly altered genes were TP53 (in about 89% of cases) and KRAS (in about 51%). Compared to rectal adenocarcinoma, anal adenocarcinoma had significantly higher rates of alterations in ERBB3, MYC, and BRCA2, and a dramatically lower rate of APC mutations, which are a hallmark of colorectal cancer. At least one potentially druggable genetic alteration was found in 40% of anal adenocarcinoma patients, spanning genes involved in the MAPK pathway, DNA damage repair, and other cancer-driving pathways.23PubMed Central. Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan
These differences matter for treatment selection. The very low rate of APC mutations suggests that simply borrowing colorectal cancer drug protocols may not always be the best strategy. Meanwhile, the relatively high frequency of BRCA2 alterations could open the door to PARP inhibitors, a drug class already used in breast and ovarian cancers with BRCA mutations. These are early findings, and clinical trials specific to anal adenocarcinoma are scarce. But genomic testing is increasingly accessible, and patients with advanced disease may benefit from having their tumors profiled to identify targetable mutations.
Immunotherapy is another area of active investigation for anal cancers broadly. HPV-positive tumors tend to trigger a stronger immune response because the virus produces foreign proteins that attract immune cells. Immune checkpoint inhibitors, which help the immune system recognize and attack cancer cells, have shown activity in metastatic anal squamous cell carcinoma and are being studied in combination regimens, alongside adoptive cell therapy and vaccine approaches.24PubMed Central. Immunotherapy in Anal Cancer For adenocarcinoma specifically, the picture is murkier. The genomic profiling study found that tumor mutational burden was high enough to potentially warrant immunotherapy in only about 7% of cases, and no tumors with the specific type of DNA repair deficiency called MSI-high were identified.23PubMed Central. Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan MSI-high status is one of the strongest predictors of response to checkpoint inhibitors, so its absence in anal adenocarcinoma is a meaningful limitation.
Living With Treatment Side Effects
Quality of life after treatment for anal cancer is an area that has received surprisingly little focused attention, particularly for patients with metastatic or recurrent disease. A systematic review looking at quality-of-life research in this population found that only three out of 23 included papers focused specifically on metastatic or recurrent anal cancer. Most of the documented symptoms related to bowel, urinary, and sexual functioning. But existing quality-of-life questionnaires failed to capture many problems patients actually experience, including nerve-related symptoms like numbness and tingling, hair loss, musculoskeletal issues, urinary incontinence, and the psychological burden of embarrassment.25SpringerLink / Support Care Cancer. Improving our understanding of the quality of life of patients with metastatic or recurrent/persistent anal cancer: a systematic review
For patients who undergo APR, life with a permanent colostomy brings its own adjustments. Sexual dysfunction is common after pelvic surgery, and radiation to the pelvic area compounds the problem. Bowel and bladder function may remain altered long after treatment ends. These are not minor footnotes. For a cancer that often requires aggressive treatment in a sensitive area of the body, the gap between what researchers measure and what patients actually deal with is wider than it should be. If you are facing this diagnosis, seeking care at a center with access to multidisciplinary support, including colorectal surgeons, radiation oncologists, medical oncologists, and survivorship specialists, can make a real difference in navigating both the treatment itself and everything that comes after.